Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Characterizing the KCC2 Interactome in a Huntington’s Disease Mouse Model

EF 2024-25

Résumé
KCC2 is the neuron specific member of the K+-Cl- cotransporter family of proteins that maintains a low intracellular Cl- concentration required for fast synaptic inhibition in the adult central nervous system. Several neurological disorders including epilepsy, neuropathic pain, and neurodegenerative diseases such as Huntington Disease (HD) exhibit Cl- dysregulation and impaired synaptic inhibition due to decreased KCC2 expression and function. KCC2 is an interactor of the huntingtin protein (HTT), whose mutant version forms insoluble aggregates that cause HD. I propose that these mutant HTT aggregates may sequester KCC2 or its major interactors. Since KCC2 is extensively regulated post-translationally, changes in the KCC2 interactome can severely affect KCC2 function and may cause the deficits in synaptic inhibition observed in HD. Therefore, identification of the changes in the KCC2 interactome during the pre-symptomatic, developmental stage of HD mice can provide insight into the pathological mechanisms that lead to Cl- dysregulation during the symptomatic phase of HD. So far, I have successfully isolated native KCC2 protein complexes from wildtype and HD mouse brain, and am currently analyzing the changes in the KCC2-interactome through mass spectrometry. From these results I will identify KCC2-protein interactions that are specifically affected in HD. Therapeutic strategies targeting KCC2 and Cl- dysregulation holds potential in treating neurological disorders including HD. Multiple candidate drugs targeting Cl- dysregulation are currently in clinical trials for treating ASD, epilepsy and schizophrenia. My research on the changes in the interactome of KCC2 has the potential to identify key molecular developmental pathways that lead to the progression of HD.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
530195
Name
Pavicic Lilliana N
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing the KCC2 Interactome in a Huntington’s Disease Mouse Model
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chloride; Gaba; Huntington'S Disease; Kcc2; Neurotransmission; Synaptic Inhibition
Abstract
KCC2 is the neuron specific member of the K+-Cl- cotransporter family of proteins that maintains a low intracellular Cl- concentration required for fast synaptic inhibition in the adult central nervous system. Several neurological disorders including epilepsy, neuropathic pain, and neurodegenerative diseases such as Huntington Disease (HD) exhibit Cl- dysregulation and impaired synaptic inhibition due to decreased KCC2 expression and function. KCC2 is an interactor of the huntingtin protein (HTT), whose mutant version forms insoluble aggregates that cause HD. I propose that these mutant HTT aggregates may sequester KCC2 or its major interactors. Since KCC2 is extensively regulated post-translationally, changes in the KCC2 interactome can severely affect KCC2 function and may cause the deficits in synaptic inhibition observed in HD. Therefore, identification of the changes in the KCC2 interactome during the pre-symptomatic, developmental stage of HD mice can provide insight into the pathological mechanisms that lead to Cl- dysregulation during the symptomatic phase of HD. So far, I have successfully isolated native KCC2 protein complexes from wildtype and HD mouse brain, and am currently analyzing the changes in the KCC2-interactome through mass spectrometry. From these results I will identify KCC2-protein interactions that are specifically affected in HD. Therapeutic strategies targeting KCC2 and Cl- dysregulation holds potential in treating neurological disorders including HD. Multiple candidate drugs targeting Cl- dysregulation are currently in clinical trials for treating ASD, epilepsy and schizophrenia. My research on the changes in the interactome of KCC2 has the potential to identify key molecular developmental pathways that lead to the progression of HD.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pavicic, Lilliana N
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~